Dr. Andreadis on the Treatment of Relapsed DLBCL

Charalambos (Babis) Andreadis, MD, MSCE
Published: Monday, Dec 03, 2018



Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma (DLBCL).

The relapsed setting of DLBCL is an area of clinical unmet need. One-third of patients in this setting can benefit, or even be cured, by transplant, but additional therapies are needed, Andreadis says. There are many patients who are ineligible for transplant or do not respond well enough to chemotherapy to benefit. Chimeric antigen receptor (CAR) T-cell therapy may be an option for these patients.  

Results from the phase II JULIET study presented at the 2018 ASH Annual Meeting showed that the CAR T-cell therapy tisagenlecleucel (Kymriah) continued to demonstrate durable objective response rates (ORR) with a median of 19 months of follow-up for patients with relapsed or refractory DLBCL. The ORR in this updated analysis was 54% (95% CI, 41%-62%) with the CD19-targeted CAR T-cell therapy.   
SELECTED
LANGUAGE


Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma (DLBCL).

The relapsed setting of DLBCL is an area of clinical unmet need. One-third of patients in this setting can benefit, or even be cured, by transplant, but additional therapies are needed, Andreadis says. There are many patients who are ineligible for transplant or do not respond well enough to chemotherapy to benefit. Chimeric antigen receptor (CAR) T-cell therapy may be an option for these patients.  

Results from the phase II JULIET study presented at the 2018 ASH Annual Meeting showed that the CAR T-cell therapy tisagenlecleucel (Kymriah) continued to demonstrate durable objective response rates (ORR) with a median of 19 months of follow-up for patients with relapsed or refractory DLBCL. The ORR in this updated analysis was 54% (95% CI, 41%-62%) with the CD19-targeted CAR T-cell therapy.   



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x